Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRAPs as a Prognostic Determinant of CRVO in Patients Treated or Not With Aflibercept
2024-516681-10-01Phase 2Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of aflibercept in central retinal vein occlusion (CRVO) (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Change in best-corrected visual acuity (BCVA). Started Nov 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on 2024-516681-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516681-10-01.